Development, Standardisation and Standardisation Project for a New Memory Assessment
Condition(s) studied
Investigational drug(s) / intervention(s)
New memory assessment: The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
Study summary
Episodic memory (EM) is a neuropsychological marker of Alzheimer's disease (AD) (Thomas-Anterion, 2006). Current tests for its assessment do not take into account the identity and emotional aspects of memory (Van der Linden et al., 2018). However, there are models that integrate links with identity, self-awareness and experience. Pause et al. (2013) propose criteria to create ecological tools, including consideration of the emotional valence of memories and the spatio-temporal context of acquisition. In line with these criteria, we have developed a new tool: the NEM (New evaluation of Episodic Memory). Preliminary studies show different response profiles on the NEM among patients (Launay et al., 2023). We now want to evaluate the relevance of this tool in the differential diagnosis of AD.
Eligibility
Primary outcome measure(s)
- Score total NEM (new memory assessment) — baseline
Sum of the episodic elements
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University hospital | Tours | France | Recruiting |
More University Hospital, Tours trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06564779 on ClinicalTrials.gov ↗ ← All trials in France